Category: Allergan Inc.
Allergan CEO David Pyott will get about $100 million in severance once his company’s merger with Actavis is completed, according to a news report.
Allergan (NYSE:AGN) Chairman and CEO David Pyott stands to earn $100 million once its multi-billion-dollar merger with Actavis (NYSE:ACT) is consummated later this year.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Cardinal Health top suitor for J&J's Cordis unit; 3M to buy Ivera Medical; Allergan name to live on post Actavis merger; Lumenis in talks to be acquired by Fosun for $480M; Uroplasty, Vision-Sciences set date for merger vote
Actavis CEO Brent Saunders tells CNBC that the company will adopt the Allergan name once the $66 billion merger closes.
There was a significant amount of turnover this year in the corner offices of medical device companies, including exits by some of medtech's biggest names.
There was a revolving door on medtech's corner office this year, with more than 35 CEOs leaving their positions through planned transitions, retirement or termination, according to a MassDevice.com analysis.
Here's a look at some of the top mergers & acquisitions stories for medical device companies this week: Will Stryker bid on Smith & Nephew this week?: J&J demands $7.2 billion from Boston Scientific as trial begins; Will Orange County's medtech scene lose its juice without Allergan?; BD-CareFusion deal passes US anti-trust waiting period; Sources: Stryker weighs bid for Smith & Nephew
, Becton Dickinson & Co.
, Boston Scientific
, CareFusion Corp.
, Guidant Corp.
, Johnson & Johnson
, Smith & Nephew
, Valeant Pharmaceuticals
, Allergan Inc.
Will the $66 billion buyout of Allergan by Actavis suck some of the juice out of Orange County, Calif., which Allergan's called home for 60 years?
Here's a look at some of the top Wall Street stories for medical device companies this week: InVivo shares soar on spinal cord study update; Actavis trumps Valeant with $66B offer for Allergan; Medtronic's Q2 results meet The Street; Venture capital investment in medtech grows in Q3